{"name":"Apellis Pharmaceuticals","slug":"apellis","ticker":"APLS","exchange":"NASDAQ","domain":"apellis.com","description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam coll","hq":"Waltham, MA","founded":0,"employees":"733","ceo":"Cedric Francois","sector":"Ophthalmology / Complement Biology","stockPrice":41.03,"stockChange":0,"stockChangePercent":0,"marketCap":"$5.3B","metrics":{"revenue":1105280000,"revenueGrowth":60.9,"grossMargin":64.3,"rdSpend":295854000,"netIncome":22388000,"cash":406196000,"dividendYield":0,"peRatio":38.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Empaveli patent cliff ($1.4B at risk)","drug":"Empaveli","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"APL-2","genericName":"APL-2","slug":"apl-2","indication":"Geographic atrophy (age-related macular degeneration)","status":"phase_3"},{"name":"APL-2, Pegcetacoplan","genericName":"APL-2, Pegcetacoplan","slug":"apl-2-pegcetacoplan","indication":"Geographic atrophy (age-related macular degeneration)","status":"phase_3"},{"name":"APL2","genericName":"APL2","slug":"apl2","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Soliris","genericName":"Soliris","slug":"soliris","indication":"Atypical hemolytic uremic syndrome","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"APL-9","genericName":"APL-9","slug":"apl-9","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"APL-2","genericName":"APL-2","slug":"apl-2","phase":"phase_3","mechanism":"APL-2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.","indications":["Geographic atrophy (age-related macular degeneration)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""},{"name":"Soliris","genericName":"Soliris","slug":"soliris","phase":"marketed","mechanism":"Complement C5","indications":["Atypical hemolytic uremic syndrome","Congenital hemolytic uremic syndrome","Neuromyelitis optica","Paroxysmal nocturnal hemoglobinuria","Refractory generalized myasthenia gravis"],"catalyst":""},{"name":"APL-2, Pegcetacoplan","genericName":"APL-2, Pegcetacoplan","slug":"apl-2-pegcetacoplan","phase":"phase_3","mechanism":"Pegcetacoplan is a complement C3 inhibitor that blocks the activation and amplification of the complement cascade by targeting C3.","indications":["Geographic atrophy (age-related macular degeneration)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""},{"name":"APL-9","genericName":"APL-9","slug":"apl-9","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APL2","genericName":"APL2","slug":"apl2","phase":"phase_2","mechanism":"APL2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Apellis reported fourth quarter and full year 2023 financial results, with net product revenue of $143.8 million and a net loss of $144.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Apellis Pharmaceuticals Announces Collaboration with the University of California, San Francisco","summary":"Apellis announced a collaboration with the University of California, San Francisco to develop new treatments for complement-mediated diseases.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"regulatory","headline":"Empaveli (pegcetacoplan) Receives Positive CHMP Opinion for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration","summary":"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Empaveli, recommending its approval for the treatment of geographic atrophy secondary to age-related macular degeneration.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQaFVqTS1RMXQtbmtEd0F3dzVkRFVmeVV2WDdKMFVjM2V6bEJwOVZUTGJ3M0JlWjJ6bVA3UWdkSG5jaGhqc1JFRWh3eU5vNmk1azRzVHFZdEFGaW9tblcyN05XZm1EbENtWjNfY2pPd1h2MlRfa01pRTdqOTFwem1OY29WS1dESFdnMnhYLUVRQW9ac0VyMk85Y2VMTjU2MGpnclB1enVpLUx1LUVQQkRqMVdRcXlnTXZYMDRCSW1NNGlQUHdK?oc=5","date":"2026-04-07","type":"deal","source":"MSN","summary":"Apellis Pharma skyrockets on Biogen deal. Is it too late to chase APLS stock? - MSN","headline":"Apellis Pharma skyrockets on Biogen deal. Is it too late to chase APLS stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE94NnRjQzAtcXdjQkpVa2FpYlRmR01DNkd0U2lNZmNpb1NnczlHOWNqMmNfeHpDTHpjbDBqV2JsbTVrNncyZktyMVpELXg5azF1UUdTaGZVV3hGNVlkSGlvTDZPbThScm1PMnJBdDR1YlJVYnhBeXYtdjlqN0x2Y0HSAYQBQVVfeXFMTXBPUVNaZC1mclJIUGtpMlcwOVBlX25UOXhWekR2ZE5qbFBFLXdhMVVwVUI2Rkxrb21LVURNS0VVdW55Y0I1cTdteExrZDZjalJzaHppdEdqQmtGTEFQZUNlU0xjME1raU83MzJPTnpBZ0t5aDBVRUxEaGF3eEJOYXdtQ0NW?oc=5","date":"2026-03-31","type":"deal","source":"CNBC","summary":"Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push - CNBC","headline":"Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOcUMya3g1UDFaSXVzZG13bHFpUlVlS2doT3ZXRXkxMm9kbVVkeVIxeFdGVnlHMnNBNkxBNUFxcW81Q1BtVEEtdWktcWVnZFFuQ29DSkprbjlfREN6RGt5QlViaVByTHl3U2ZhVzNPbml6RVBsSEllcDRDTU9yMEk3Y1dTNzM2aENqQkVNYkR3eEtQNlNKYUhnQzF2YkltUQ?oc=5","date":"2026-03-31","type":"deal","source":"Investor's Business Daily","summary":"Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily","headline":"Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPakpLRXlsYVRWR0hmV0lxTm54MmVhZFQ1Nzg5V1owMnhSY2g3S3ROQTNnQUQ3UTlvWnZmdC16RkhPUXRaUGszeEdMMmxiUzVqMmdfSFc0MUdIT3Zva2lwdXNlMjQtS1ZsNFBoNWlJTzAyQ0tqVG44TjNNVnFOY2dLSENXajJ0Q2EzQ3A2c21KV2U1ekJRd3R2Nko5bUhBUEtGWGllMVU0U2dSRGFaNV9lY01JZ003SVFFWkZV?oc=5","date":"2026-03-31","type":"deal","source":"Barchart","summary":"Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? - Barchart","headline":"Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNN09mc0JFRHVLbklFSTZDSnhMTG9RczdGRHhVQXJNdE5oRmlSV3ZIM0tPaWFiSl9UVm5TY240NEE2VUwyWHJWX0NCckdBY3ZjS1hraFBLWjFLY1R2Zi10enhNb0hGTVphWTdPTjJ4MjNMdU5rd0JqTEl5T0JuZEp0MW1UWmVCVldITXlnSVdnQU9qUklGbUUzSGRxXy1NZ1dDYkhr?oc=5","date":"2026-03-31","type":"deal","source":"inkl.com","summary":"Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? - inkl.com","headline":"Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxONXJiOThQVThac2VyVl9kRkFKelVFSFQ1VHl1SG5ZVFE2Ui1fUFBWUFEwbHdsMHBIdkJ4TkZzOUZfTkgybzB2X3dVaVp1VE1lNDFIZFJlMUZaYmcwbi01c0xueXJIRVNyeTIzZlBOSjZ2SUlQcEUtNXlIV2FEekxWdnlRc1ZxYUZ0MC10bg?oc=5","date":"2026-03-10","type":"pipeline","source":"Yahoo Finance","summary":"Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Yahoo Finance","headline":"Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNY2dPOURkaE9PU0NsN3FrTTZMSkxrc1dtaVAyblR0dzV6azJOQVpPVTlWbnlpOThteERhZW5xWFcydGJVVkM5ZmIxWHhENGpJdWV6cFlSeXZqam8tNlFqcXZUd0d3U1ZZUlZCZ1lOTkRPMXA1VkFzQXI3VlpHNmpkbjNHSEdvRVllbkpVVmQzZVVxV0Q1b3dpcFFKWWVRdnEtOWVYYkQydnVUUkRSREE0ZlhyZw?oc=5","date":"2026-01-23","type":"pipeline","source":"Investing.com","summary":"Apellis Pharma CEO Francois sells $592k in shares - Investing.com","headline":"Apellis Pharma CEO Francois sells $592k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPakZzbEotZ3JFNk9TbXdaWFJWMjJHakUwd3dsc0JTT0lfeXlYaEhtWndmazRnT0doVjRfejE1MEtLTVhlVERvUmhyTHFDa3BXeXpuS2dzUi1lNnZYYU5VSGc0SmhSUjNFaHlQRl9BWTZuNjFqUjcweTQwQ2lLaV9kSHNBTEVvQUJObnY2SzQxTm15U1dQOVJQWEdCWjJ2Zw?oc=5","date":"2026-01-17","type":"regulatory","source":"24/7 Wall St.","summary":"Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - 24/7 Wall St.","headline":"Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOZHlWWWlOdzAyODhjWWtPSjFDYUdWSERfNlMxemNheF8xNVFXamRVZHdvQV9DUktHeUExOG9GVHNJQ1dOZ2gtWDFRV0x6eG83VFdiOEljNzhob21RUnhYUHFtUTlmWGpPUC0zMkNUY0hhUGk1N3ZtWmdkbWRqYVp6OFlBNUJScW42dmdIRTZJME45NmVsOWpR?oc=5","date":"2026-01-15","type":"pipeline","source":"Finviz","summary":"Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz","headline":"Apellis Stock Crashes 23% in a Week: Here's What You Should Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVXE3Q2RUSG5zdkpmbWZNSExOTGlrNWZ3SkVkVHZmc0R2Y21xNzVpMlJxMjZGSzQ1bk5iUGFPU1pLWXRabkhxVmoyZFBhZkFQNktZWVNsa0ROOG5lMGRzMUdCTUZSdjhXejNHcU5wb1dTRUw1X1FMWmtoek5OeDNyR3hvejBwampNNUNoZkp6dkUwaVU1enJHVFBXWElqSTFMLUpacUdsMkQ?oc=5","date":"2025-12-12","type":"pipeline","source":"Seeking Alpha","summary":"Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha","headline":"Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPbkE4dTBpM2Z2aXJJemgzV3BrRmV5ZXlRelpwamlRckpmaUZqc2JlTVNOUzU1bXRFSDN3MGtGUmFhZElicExTWGJQQWg4LW5uUWdiZnN3clhONWdOejE2VHA5QlNqOVVqUm1ucmx6djY2R1haWGpGOTlvV2hVOTRzbHNRS0hjRDROSkhGSmZ0akMwZExEZWwza0tvbV91SG94d1hZYUgtMWlMdUw4X1otcmtjVHgyN25pbXM2TXN0NHJaYzNnUEtENmhScDVnLVhTVjRoLVhoTmdOMFQtYlhKQkk5OHFjdTA?oc=5","date":"2025-11-12","type":"pipeline","source":"Benzinga","summary":"What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga","headline":"What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS)","sentiment":"neutral"}],"patents":[{"drugName":"Empaveli","drugSlug":"pegcetacoplan","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":5,"phaseCounts":{"phase_3":2,"marketed":1,"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Alcon","Novartis"],"therapeuticFocus":["Ophthalmology","Complement Biology"],"financials":{"source":"sec_edgar+yahoo","revenue":1003782000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1003782000,"period":"2025-12-31"},{"value":781367000,"period":"2024-12-31"},{"value":781367000,"period":"2024-12-31"},{"value":396591000,"period":"2023-12-31"},{"value":396591000,"period":"2023-12-31"}],"grossProfit":901546000,"grossProfitHistory":[{"period":"2025-12-31","value":901546000},{"period":"2024-12-31","value":663644000},{"period":"2023-12-31","value":338081000},{"period":"2022-12-31","value":69786000}],"rdSpend":295854000,"rdSpendHistory":[{"period":"2025-12-31","value":295854000},{"period":"2024-12-31","value":327570000},{"period":"2023-12-31","value":354387000},{"period":"2022-12-31","value":387236000}],"sgaSpend":550265000,"operatingIncome":55427000,"operatingIncomeHistory":[{"period":"2025-12-31","value":55427000},{"period":"2024-12-31","value":-164979000},{"period":"2023-12-31","value":-517121000},{"period":"2022-12-31","value":-594613000}],"netIncome":22388000,"netIncomeHistory":[{"period":"2025-12-31","value":22388000},{"period":"2024-12-31","value":-197878000},{"period":"2023-12-31","value":-528628000},{"period":"2022-12-31","value":-652172000}],"eps":0.18,"epsHistory":[{"period":"2025-12-31","value":0.18},{"period":"2024-12-31","value":-1.6},{"period":"2023-12-31","value":-4.45},{"period":"2022-12-31","value":-6.15}],"cash":466233000,"cashHistory":[{"period":"2025-12-31","value":466233000},{"period":"2024-12-31","value":411290000},{"period":"2023-12-31","value":351185000},{"period":"2022-12-31","value":551801000}],"totalAssets":1075257000,"totalLiabilities":705110000,"totalDebt":474360000,"equity":370147000,"operatingCashflow":45327000,"operatingCashflowHistory":[{"period":"2025-12-31","value":45327000},{"period":"2024-12-31","value":-87866000},{"period":"2023-12-31","value":-594735000},{"period":"2022-12-31","value":-513745000}],"capex":-313000,"capexHistory":[{"period":"2025-12-31","value":-313000},{"period":"2024-12-31","value":-403000},{"period":"2023-12-31","value":-773000},{"period":"2022-12-31","value":-1524000}],"freeCashflow":45014000,"dividendsPaid":null,"buybacks":null,"employees":733,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":147103000,"ebit":-47791000,"ebitda":-47464000,"period":"2025-12-31","revenue":199913000,"epsBasic":null,"netIncome":-58951000,"rdExpense":74233000,"epsDiluted":null,"grossProfit":170194000,"operatingIncome":-51142000},{"sga":142678000,"ebit":227596000,"ebitda":227935000,"period":"2025-09-30","revenue":458578000,"epsBasic":1.71,"netIncome":215715000,"rdExpense":68186000,"epsDiluted":1.67,"grossProfit":434047000,"operatingIncome":223183000},{"sga":131139000,"ebit":-30533000,"ebitda":-30087000,"period":"2025-06-30","revenue":178494000,"epsBasic":-0.33,"netIncome":-42151000,"rdExpense":67015000,"epsDiluted":-0.33,"grossProfit":164868000,"operatingIncome":-33286000},{"sga":129345000,"ebit":-80835000,"ebitda":-80389000,"period":"2025-03-31","revenue":166797000,"epsBasic":-0.74,"netIncome":-92225000,"rdExpense":86420000,"epsDiluted":-0.74,"grossProfit":132437000,"operatingIncome":-83328000},{"sga":121482000,"ebit":-24533000,"ebitda":-24079000,"period":"2024-12-31","revenue":212528000,"epsBasic":null,"netIncome":-36353000,"rdExpense":76354000,"epsDiluted":null,"grossProfit":171672000,"operatingIncome":-26164000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.46,"netIncome":null,"rdExpense":null,"epsDiluted":-0.46,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":41.03,"previousClose":41.03,"fiftyTwoWeekHigh":41.14,"fiftyTwoWeekLow":16.1,"fiftyTwoWeekRange":"16.1 - 41.14","fiftyDayAverage":32.36,"twoHundredDayAverage":25.86,"beta":-0.25,"enterpriseValue":5322272768,"forwardPE":-120.7,"priceToBook":12.65,"priceToSales":4.75,"enterpriseToRevenue":4.82,"enterpriseToEbitda":31.94,"pegRatio":0,"ebitda":166624992,"ebitdaMargin":15.1,"freeCashflow":-63650124,"operatingCashflow":37771000,"totalDebt":475756000,"debtToEquity":114.7,"currentRatio":3.63,"returnOnAssets":10.9,"returnOnEquity":46,"analystRating":"2.9 - Hold","recommendationKey":"hold","numberOfAnalysts":15,"targetMeanPrice":40.93,"targetHighPrice":41,"targetLowPrice":40,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.3,"institutionHeldPercent":102.7,"sharesOutstanding":128021277,"floatShares":83220231,"sharesShort":10752810,"shortRatio":1.15,"shortPercentOfFloat":8.4,"epsTrailing":1.07,"epsForward":-0.34,"revenuePerShare":8.72,"bookValue":3.24,"officers":[{"age":53,"name":"Dr. Cedric  Francois M.D., Ph.D.","title":"Co-Founder, President, CEO & Director"},{"age":52,"name":"Mr. Alec  Machiels J.D., MBA","title":"Co-Founder & Director"},{"age":54,"name":"Mr. Timothy E. Sullivan","title":"CFO & Treasurer"},{"age":52,"name":"Mr. David O. Watson Esq., J.D.","title":"General Counsel & Secretary"},{"age":null,"name":"Ms. Kelley  Boucher","title":"Chief People Officer"},{"age":57,"name":"Dr. Caroline R. Baumal M.D.","title":"Chief Medical Officer"},{"age":55,"name":"Dr. Pascal  Deschatelets Ph.D.","title":"Co-Founder & Chief Scientific Officer"},{"age":58,"name":"Mr. James G. Chopas CPA","title":"VP, Corporate Controller & Chief Accounting Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://apellis.com","phone":"617 977 5700"}}